HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herukka, S.-K. Articles by Pirttilä, T. Search for Related Content PubMed PubMed Citation Articles by Herukka, S.-K. Articles by Pirttilä, T. Related Collections Alzheimer's disease MCI (mild cognitive impairment)

CSF Aß42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

From the Department of Neuroscience and Neurology (Drs. Hallikainen, Soininen, and Pirttilä, S.-K. Herukka), University of Kuopio, and Department of Neurology (Drs. Soininen and Pirttilä), Kuopio University Hospital, Finland.

Address correspondence and reprint requests to Dr. T. Pirttilä, Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland; e-mail: tuula.pirttila{at}kuh.fi

Baseline CSF amyloid ß-peptide-42 (Aß42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Aß42 and P-tau.

Supported by the Kuopio University Hospital (EVO grant nos. 5772720 and 5772725).

Received June 3, 2004. Accepted in final form December 14, 2004.

This article has been cited by other articles:

				J. M. Ringman, S. G. Younkin, D. Pratico, W. Seltzer, G. M. Cole, D. H. Geschwind, Y. Rodriguez-Agudelo, B. Schaffer, J. Fein, S. Sokolow, et al. Biochemical markers in persons with preclinical familial Alzheimer disease Neurology, July 8, 2008; 71(2): 85 - 92. [Abstract] [Full Text] [PDF]

				M. Ewers, K. Buerger, S. J. Teipel, P. Scheltens, J. Schroder, R. P. Zinkowski, F. H. Bouwman, P. Schonknecht, N.S.M. Schoonenboom, N. Andreasen, et al. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI Neurology, December 11, 2007; 69(24): 2205 - 2212. [Abstract] [Full Text] [PDF]

				F. H. Bouwman, W. M. van der Flier, N.S.M. Schoonenboom, E. J. van Elk, A. Kok, F. Rijmen, M. A. Blankenstein, and P. Scheltens Longitudinal changes of CSF biomarkers in memory clinic patients Neurology, September 4, 2007; 69(10): 1006 - 1011. [Abstract] [Full Text] [PDF]

				N. M. Kemppainen, S. Aalto, I. A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment Neurology, May 8, 2007; 68(19): 1603 - 1606. [Abstract] [Full Text] [PDF]

				T. S.M. Reijn, M. O. Rikkert, W. J.A. van Geel, D. de Jong, and M. M. Verbeek Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid {beta}42 and Tau Proteins Clin. Chem., May 1, 2007; 53(5): 859 - 865. [Abstract] [Full Text] [PDF]

				A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman Cerebrospinal Fluid tau/beta-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults Arch Neurol, March 1, 2007; 64(3): 343 - 349. [Abstract] [Full Text] [PDF]